SCHEMBL10205895

SCHEMBL10205895

Cc1cc(Nc2ncc(C(F)(F)F)c(NCc3cccc4c3C(C)(C)C(=O)N4)n2)ccc1C1CCN(CC(C)(C)O)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 15/20 0.46
▸ PTK2B Q14289 14/20 0.46
▸ AURKA O14965 2/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ FLT3 P36888 5/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ NTRK1 P04629 2/20 0.42
▸ TYK2 P29597 2/20 0.42
▸ KDR P35968 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ NTRK2 Q16620 2/20 0.42
▸ CDK1 P06493 2/20 0.42
▸ CDK7 P50613 2/20 0.42
▸ PLK4 O00444 1/20 0.42
▸ PDPK1 O15530 1/20 0.42
▸ DAPK3 O43293 1/20 0.42
▸ ROCK2 O75116 1/20 0.42
▸ STK16 O75716 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10205873 0.92 PTK2 (0.40) PTK2PTK2BAURKABRD4FLT4
SCHEMBL10205208 0.91 JAK3 (0.41) PTK2NTRK1JAK3NTRK2INSR
SCHEMBL10205211 0.91 CDK1 (0.40) PTK2PTK2BAURKABRD4JAK2
SCHEMBL10205877 0.91 PTK2 (0.39) PTK2PTK2BAURKABRD4INSR
SCHEMBL10205874 0.89 PTK2 (0.39) PTK2PTK2BJAK2NTRK1TYK2
SCHEMBL10207069 0.88 PTK2 (0.39) PTK2PTK2BJAK2NTRK1TYK2
SCHEMBL10205911 0.88 PTK2 (0.47) PTK2PTK2BFLT4LRRK2ALK
SCHEMBL10205093 0.88 PTK2 (0.44) PTK2PTK2BAURKABRD4JAK2
SCHEMBL10205876 0.88 PTK2 (0.48) PTK2PTK2BAURKABRD4FLT3
SCHEMBL10205872 0.86 PTK2 (0.46) PTK2PTK2BAURKABRD4FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 PTK2 1524/4885PTK2B 831/4885AURKA 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback